Meeting
2020 Gastrointestinal Cancers Symposium
MT-5111: A novel HER2 targeting engineered toxin body in clinical development.
Authors
Roger J. Waltzman
Molecular Templates, Inc. Ste. 100, Austin, TX
Roger J. Waltzman , Asis Sarkar , Eric T Williams , Aimee T. Iberg , Jack T. Higgins , Erin K. Willert
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Esophageal and Gastric Cancer and Other GI Cancers
Track
Esophageal and Gastric Cancer,Other GI Cancer
Sub Track
Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 38, 2020 (suppl 4; abstr 433)
Abstract #
433
Poster Bd #
G22
Abstract Disclosures
Similar Posters
Poster
2020 Gastrointestinal Cancers Symposium
A phase I open-label study to investigate safety and tolerability, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity of MT-5111 in subjects with HER-2 positive tumors.
First Author: Brian Andrew Van Tine
Poster
2023 ASCO Annual Meeting
A systematic review and meta-analysis of intrathecal versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases.
First Author: Anna-Maria Lazaratos
Poster
2024 ASCO Annual Meeting
The design, preclinical study and phase I dose escalation plan of a HER2 targeted immunoliposome (HF-K1) for HER2 low solid tumor treatment.
First Author: Shanshan Jin
Poster
2023 ASCO Annual Meeting
A phase 1, first-in-human, open label, escalation and expansion study of ORM-5029, a highly potent GSPT1 degrader targeting HER2, in patients with HER2-expressing advanced solid tumors.
First Author: Sara A. Hurvitz